GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » 3-Year FCF Growth Rate

Infant Bacterial Therapeutics AB (OSTO:IBT B) 3-Year FCF Growth Rate : -19.20% (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB 3-Year FCF Growth Rate?

Infant Bacterial Therapeutics AB's Free Cash Flow per Share for the three months ended in Mar. 2025 was kr-2.08.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -19.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -14.80% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -7.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 11 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Infant Bacterial Therapeutics AB was 30.80% per year. The lowest was -76.60% per year. And the median was -10.20% per year.


Competitive Comparison of Infant Bacterial Therapeutics AB's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infant Bacterial Therapeutics AB's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's 3-Year FCF Growth Rate falls into.


;
;

Infant Bacterial Therapeutics AB 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Infant Bacterial Therapeutics AB  (OSTO:IBT B) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Infant Bacterial Therapeutics AB 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Infant Bacterial Therapeutics AB Business Description

Traded in Other Exchanges
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines